المؤلفون: Fidias, Panos, Pennell, Nathan A., Boral, Anthony L., Shapiro, Geoffrey I., Skarin, Arthur T., Eder, Joseph P., Jr, Kwoh, T Jesse, Geary, Richard S., Johnson, Bruce E., Lynch, Thomas J., Supko, Jeffrey G.

المصدر: In Journal of Thoracic Oncology September 2009 4(9):1156-1162

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Eder Jr., Joseph P., Ryan, David P., Appleman, Leonard, Zhu, Andrew X., Puchalski, Thomas, Xiaoying He, Sonnichsen, Daryl S., Cooper, Michael, Wright, John, Clark, Jeffrey W., Supko, Jeffrey G., Eder, Joseph P Jr, He, Xiaoying

المصدر: Cancer Chemotherapy & Pharmacology; Jul2006, Vol. 58 Issue 1, p107-116, 10p, 3 Charts, 2 Graphs

مصطلحات موضوعية: PATIENTS, DIMETHYLALLYLTRANSTRANSFERASE, BLOOD cells, PHARMACOKINETICS, HYPONATREMIA, DRUG dosage

المؤلفون: Cunningham C; Tyler Cancer Center, Texas, USA., Appleman LJ, Kirvan-Visovatti M, Ryan DP, Regan E, Vukelja S, Bonate PL, Ruvuna F, Fram RJ, Jekunen A, Weitman S, Hammond LA, Eder JP Jr

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2005 Nov 01; Vol. 11 (21), pp. 7825-33.

نوع المنشور: Clinical Trial, Phase I; Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Print ISSN: 1078-0432 (Print) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*administration & dosage , Antineoplastic Agents/*pharmacokinetics , Neoplasms/*drug therapy , Oligopeptides/*administration & dosage , Oligopeptides/*pharmacokinetics, Adult ; Aged ; Aged, 80 and over ; Area Under Curve ; Dose-Response Relationship, Drug ; Female ; Humans ; Infusions, Intravenous ; Male ; Maximum Tolerated Dose ; Middle Aged ; Models, Chemical ; Time Factors

المؤلفون: Eder JP Jr; Dana-Farber/Harvard Cancer Care, Harvard Medical School, Boston, MA 02115, USA. jeder@partners.org, Garcia-Carbonero R, Clark JW, Supko JG, Puchalski TA, Ryan DP, Deluca P, Wozniak A, Campbell A, Rothermel J, LoRusso P

المصدر: Investigational new drugs [Invest New Drugs] 2004 Apr; Vol. 22 (2), pp. 139-50.

نوع المنشور: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print Cited Medium: Print ISSN: 0167-6997 (Print) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*adverse effects , Neoplasms/*drug therapy , Staurosporine/*analogs & derivatives, Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/blood ; Area Under Curve ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drugs, Investigational/administration & dosage ; Drugs, Investigational/adverse effects ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Fluorouracil/blood ; Gastrointestinal Diseases/blood ; Gastrointestinal Diseases/chemically induced ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Neoplasms/blood ; Staurosporine/administration & dosage ; Staurosporine/adverse effects ; Staurosporine/blood

المؤلفون: Ryan DP; Massachusetts General Hospital, Boston, Massachusetts 02114, USA. dpryan@partners.org, Eder JP Jr, Puchlaski T, Seiden MV, Lynch TJ, Fuchs CS, Amrein PC, Sonnichsen D, Supko JG, Clark JW

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2004 Apr 01; Vol. 10 (7), pp. 2222-30.

نوع المنشور: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Print ISSN: 1078-0432 (Print) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Alkyl and Aryl Transferases/*antagonists & inhibitors , Antineoplastic Agents/*pharmacology , Benzodiazepines/*pharmacology , Imidazoles/*pharmacology, Adult ; Aged ; Antineoplastic Agents/pharmacokinetics ; Benzodiazepines/pharmacokinetics ; Dose-Response Relationship, Drug ; Enzyme Inhibitors/pharmacology ; Farnesyltranstransferase ; Female ; Humans ; Imidazoles/pharmacokinetics ; Male ; Maximum Tolerated Dose ; Middle Aged ; Models, Chemical ; Time Factors

المؤلفون: Schuch G; Department of Urology, Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA., Heymach JV, Nomi M, Machluf M, Force J, Atala A, Eder JP Jr, Folkman J, Soker S

المصدر: Cancer research [Cancer Res] 2003 Dec 01; Vol. 63 (23), pp. 8345-50.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Print ISSN: 0008-5472 (Print) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Cell Movement/*drug effects , Endostatins/*pharmacology , Endothelium, Vascular/*cytology , Stem Cells/*cytology , Vascular Endothelial Growth Factor A/*physiology, Animals ; Cell Movement/physiology ; Endostatins/administration & dosage ; Endostatins/biosynthesis ; Endostatins/genetics ; Endothelium, Vascular/drug effects ; Humans ; Mice ; Mice, SCID ; Mice, Transgenic ; Stem Cells/drug effects ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Vascular Endothelial Growth Factor A/pharmacology

المؤلفون: Supko JG; Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA. jsupko@partners.org, Eder JP Jr, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2003 Nov 01; Vol. 9 (14), pp. 5178-86.

نوع المنشور: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Print ISSN: 1078-0432 (Print) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*pharmacokinetics , Neoplasm Recurrence, Local/*metabolism , Neoplasms/*metabolism , Purine Nucleosides/*pharmacokinetics, Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/toxicity ; Area Under Curve ; Drug Administration Schedule ; Female ; Humans ; Infusions, Intravenous ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Neoplasms/drug therapy ; Purine Nucleosides/administration & dosage ; Purine Nucleosides/toxicity ; Salvage Therapy

المؤلفون: Eder JP Jr; Division of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. jelder@partners.org, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2002 Sep 15; Vol. 20 (18), pp. 3772-84.

نوع المنشور: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print Cited Medium: Print ISSN: 0732-183X (Print) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors/*therapeutic use , Collagen/*therapeutic use , Neoplasms/*drug therapy , Peptide Fragments/*therapeutic use, Adult ; Aged ; Angiogenesis Inhibitors/adverse effects ; Angiogenesis Inhibitors/pharmacokinetics ; Collagen/adverse effects ; Collagen/pharmacokinetics ; Creatinine/metabolism ; Endostatins ; Endothelial Growth Factors/urine ; Female ; Fibroblast Growth Factor 2/urine ; Humans ; Infusions, Intravenous ; Lymphokines/urine ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Neoplasms/pathology ; Peptide Fragments/adverse effects ; Peptide Fragments/pharmacokinetics ; Recombinant Proteins/therapeutic use ; Time Factors ; Tissue Distribution ; Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors

المؤلفون: Seiden MV; Department of Medicine, Massachusetts General Hospital, Boston 02114, USA. mseiden@partners.org, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D, Skarin A, Eder JP Jr

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2002 Mar; Vol. 8 (3), pp. 691-7.

نوع المنشور: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Print ISSN: 1078-0432 (Print) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Esophageal Neoplasms/*drug therapy , Lung Neoplasms/*drug therapy , Neoplasm Recurrence, Local/*drug therapy , Ovarian Neoplasms/*drug therapy, Adult ; Aged ; Antigens, Neoplasm ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Area Under Curve ; DNA Primers/metabolism ; DNA Topoisomerases, Type I/genetics ; DNA Topoisomerases, Type I/metabolism ; DNA Topoisomerases, Type II/genetics ; DNA Topoisomerases, Type II/metabolism ; DNA-Binding Proteins ; Dose-Response Relationship, Drug ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Doxorubicin/pharmacokinetics ; Esophageal Neoplasms/metabolism ; Esophageal Neoplasms/pathology ; Female ; Humans ; Infusions, Intravenous ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/pathology ; RNA, Messenger/metabolism ; RNA, Neoplasm/metabolism ; Reverse Transcriptase Polymerase Chain Reaction ; Safety ; Topotecan/administration & dosage ; Topotecan/adverse effects ; Topotecan/pharmacokinetics ; Treatment Outcome